Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) – Analysts at Jefferies Group issued their Q3 2017 earnings estimates for Valeant Pharmaceuticals International in a research report issued to clients and investors on Wednesday. Jefferies Group analyst D. Steinberg expects that the specialty pharmaceutical company will earn $0.83 per share for the quarter. Jefferies Group has a “Buy” rating and a $18.00 price objective on the stock. Jefferies Group also issued estimates for Valeant Pharmaceuticals International’s Q4 2017 earnings at $0.80 EPS, FY2018 earnings at $3.33 EPS, FY2019 earnings at $3.85 EPS, FY2020 earnings at $4.49 EPS and FY2021 earnings at $5.10 EPS.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The company had revenue of $2.23 billion during the quarter, compared to the consensus estimate of $2.23 billion. During the same period in the previous year, the firm posted ($0.88) earnings per share. Valeant Pharmaceuticals International’s quarterly revenue was down 7.7% compared to the same quarter last year. ILLEGAL ACTIVITY WARNING: “Valeant Pharmaceuticals International, Inc. Expected to Post Q3 2017 Earnings of $0.83 Per Share (NYSE:VRX)” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/valeant-pharmaceuticals-international-inc-expected-to-post-q3-2017-earnings-of-0-83-per-share-nysevrx/1471530.html.

VRX has been the subject of several other research reports. J P Morgan Chase & Co set a $10.00 price target on shares of Valeant Pharmaceuticals International and gave the stock a “hold” rating in a research report on Monday, July 17th. BTIG Research reissued a “neutral” rating on shares of Valeant Pharmaceuticals International in a research report on Wednesday, May 10th. Mizuho reissued an “underperform” rating and issued a $8.00 price target (down previously from $9.00) on shares of Valeant Pharmaceuticals International in a research report on Monday, April 17th. BMO Capital Markets reissued a “market perform” rating on shares of Valeant Pharmaceuticals International in a research report on Wednesday, May 10th. Finally, Guggenheim assumed coverage on shares of Valeant Pharmaceuticals International in a research note on Saturday, June 17th. They set a “buy” rating and a $18.00 price objective on the stock. Four analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Valeant Pharmaceuticals International has a consensus rating of “Hold” and a consensus target price of $17.31.

Valeant Pharmaceuticals International (VRX) opened at 13.81 on Friday. The firm’s market capitalization is $4.80 billion. The firm has a 50-day moving average price of $16.61 and a 200-day moving average price of $13.38. Valeant Pharmaceuticals International has a 52 week low of $8.31 and a 52 week high of $32.74.

A number of institutional investors have recently made changes to their positions in VRX. Gruss & Co. Inc. acquired a new position in shares of Valeant Pharmaceuticals International during the first quarter worth about $104,000. Financial Architects Inc raised its stake in Valeant Pharmaceuticals International by 18.6% in the first quarter. Financial Architects Inc now owns 9,550 shares of the specialty pharmaceutical company’s stock valued at $105,000 after buying an additional 1,500 shares during the period. Harbor Advisors LLC purchased a new stake in Valeant Pharmaceuticals International during the first quarter valued at $110,000. NEXT Financial Group Inc raised its stake in Valeant Pharmaceuticals International by 6.2% in the second quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock valued at $178,000 after buying an additional 600 shares during the period. Finally, WMS Partners LLC purchased a new stake in Valeant Pharmaceuticals International during the first quarter valued at $116,000. 51.14% of the stock is currently owned by hedge funds and other institutional investors.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Earnings History and Estimates for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.